Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $192 | $155 | $52 | $92 |
| - Cash | $6 | $19 | $14 | $14 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $186 | $136 | $38 | $78 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $1 | -$3 | -$3 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.083 | -0.11 | -0.18 | -0.23 |
| % Growth | 24.9% | 38.9% | 21.7% | – |
| Operating Cash Flow | -$2 | -$2 | -$0 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$2 | -$0 | -$5 |